Scynexis to get new CEO

Durham drug developer Scynexis has named Dr. Marco Taglietti as CEO to replace Yves Ribeill, who ran the company for 15 years. Ribeill will remain the company's president and continue to serve on the board of directors.

Scynexis licenses drug compounds

Durham drug developer Scynexis reached a deal to license its experimental viral disease treatment to Waterstone Pharmaceutical for $1 million for the first compound and a potential $500,000 on the second.

Scynexis Hits Public Markets

Durham pharmaceutical company Scynexis hit the public markets Friday, more than a month after it initially filed for an initial public offering.

Scynexis set to go public

Durham Drug developer Scynexis plan to go public this week.

Scynexis Files $55M IPO

Durham pharmaceutical company Scynexis filed to go public with the intent to raise $55 million through an initial public offering.

Scynexis Names New Executive for Animal Health

Durham drug discovery company Scynexis has appointed Dr. Vivian Doelling as vice president of animal health.

Scynexis Regains Rights to Antifungal Compound

Durham company Scynexis has nabbed development and commercialization rights for an antifungal platform that it previously sold to Merck in 2002.